2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation Eculizumab - Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Phase 1 / Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2015-02-01 | 2025-11-20 | |
| Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Standard of care treatment, eculizumab - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2011-05-01 | 2017-02-23 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)
Assistance Publique - Hôpitaux de Paris (1) · University of North Carolina, Chapel Hill (1)
United States (1)
P01DK058335 (1)